Galapagos NV (NASDAQ:GLPG) Ratings Summary as of Apr 17, 2018

April 17, 2018 - By Nellie Rakes

Galapagos NV (NASDAQ:GLPG) Corporate Logo

Galapagos NV (NASDAQ:GLPG) Ratings Coverage

In total 3 analysts cover Galapagos NV (NASDAQ:GLPG). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 6 are the (NASDAQ:GLPG)’s analyst reports since October 27, 2017 according to StockzIntelligence Inc. On Wednesday, February 7 the company was maintained by BTIG Research. On Friday, October 27 Stifel Nicolaus maintained Galapagos NV (NASDAQ:GLPG) with “Buy” rating. On Friday, October 27 the stock of Galapagos NV (NASDAQ:GLPG) earned “Hold” rating by RBC Capital Markets. The stock rating was maintained by BTIG Research with “Buy” on Monday, November 20. On Tuesday, November 7 the stock of Galapagos NV (NASDAQ:GLPG) has “Buy” rating given by BTIG Research. On Monday, January 8 the stock has “Buy” rating by BTIG Research. Listed here are Galapagos NV (NASDAQ:GLPG) PTs and latest ratings.

07/02/2018 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
08/01/2018 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
20/11/2017 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
07/11/2017 Broker: BTIG Research Rating: Buy New Target: $118.0 Maintain
27/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $120.0 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $102.0 Maintain

On during the last trading session the stock decreased $5.47 or 5.41%, reaching $95.6.Galapagos NV has 261,591 shares volume, 147.24% up from normal. GLPG is uptrending and has moved 18.07% since April 17, 2017. The stock outperformed the S&P 500 by 6.52%.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands.The firm is valued at $4.94 billion. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis patients in Phase Ib trial.Currently it has negative earnings. The firm has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106.

Galapagos NV (NASDAQ:GLPG) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: